基本情報
- CAS
514-36-3- 標準SMILES
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C- InChIKey
SYWHXTATXSMDSB-GSLJADNHSA-N- 分子式
- C23H31FO6
- 平均分子量
- 422.5 g/mol
- 単同位体質量
- 422.21046687
概要
Fludrocortisone acetate is an acetate ester resulting from the formal condensation of the primary hydroxy group of fludrocortisone with acetic acid. A synthetic corticosteroid, it has glucocorticoid actions about 10 times as potent as hydrocortisone, while its mineralocorticoid actions are over 100 times as potent. It is used in partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenal hyperplasia. It is a tertiary alpha-hydroxy ketone, a mineralocorticoid, a 17alpha-hydroxy steroid, an 11beta-hydroxy steroid, a 20-oxo steroid, an acetate ester, a 3-oxo-Delta(4) steroid and a fluorinated steroid. It is functionally related to a fludrocortisone.
名称と識別子
- 優先名称
- Fludrocortisone Acetate
- IUPAC
- [2-[(8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
- 現地名
- フルドロコルチゾン酢酸エステル
- 英語名
- Fludrocortisone acetate
- 分子式
- C23H31FO6
- 分子量
- 422.49
名称と別名
FLUDROCORTISONE ACETATE514-36-3ScherofluronAlflorone acetateFlorinef acetateFludrocortisone 21-acetateCortef-FFluorocortisol acetateFluorocortisone acetateFluohydrocortisone acetate9alpha-Fluorohydrocortisone acetate9alpha-Fluorohydrocortisone 21-acetate
名称をさらに表示
21-(アセチルオキシ)-9-フルオロ-11β,17-ジヒドロキシプレグナ-4-エン-3,20-ジオン9-フルオロコルチソール21-アセタートフルドロコルチゾン酢酸エステル酢酸フルドロコルチゾン9α-フルオロヒドロコルチゾンアセタート9α-フルオロ-11β,17α,21-トリヒドロキシプレグナ-4-エン-3,20-ジオン21-アセタート21-アセトキシ-9α-フルオロ-11β,17α-ジヒドロキシプレグナ-4-エン-3,20-ジオンフルドロコルチゾンアセタートアルフロロンアセタートスケロフルロンフロリンfフルドロコルチゾン酢酸エステル (JP17)2-[(1R,3aS,3bS,9aS,9bR,10S,11aS)-9b-フルオロ-1,10-ジヒドロキシ-9a,11a-ジメチル-7-オキソ-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-シクロペンタ[a]フェナントレン-1-イル]-2-オキソエチル アセタート9-FLUOROHYDROCORTISONE ACETATE
物性
構造計算による物性
- XLogP
- 1.7
- 極性表面積
- 101 Ų
- 水素結合供与体数
- 2
- 水素結合受容体数
- 7
- 回転可能結合数
- 4
- 重原子数
- 30
- 形式電荷
- 0
- 複雑度
- 838
実験および物理化学的性質
DrugsPharmaceuticals -> Dermatologicals -> Corticosteroids, dermatological preparations
LipidsLipids -> Sterol Lipids [ST] -> Steroids [ST02] -> C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives [ST0203]
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Collision Cross Section189.7 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
物理化学的性質
- 融点
- 233 · 233-234°C
- 沸点
- 575.1 · 575.1±50.0 °C(Predicted)
- 比旋光度
- 23 · D23 +123° (c = 0.64 in chloroform)
- 比重(密度)
- 1.0953 · 1.0953 (rough estimate)
- 屈折率
- 1.598 · 1.5980 (estimate)
- 貯蔵温度
- 2 · 2-8°C
- 溶解性
- 水にほとんど溶けず、無水エタノールにやや溶けにくい。
- 酸解離定数(Pka)
- 12.06 · 12.06±0.70(Predicted)
- 外見
- Solid
- 色
- ホワイトからオフホワイト
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Warning
H302 (95.2%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P264, P270, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 42 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
危険有害性情報
Other Safety InformationIMAP assessments - Pregn-4-ene-3,20-dione, 21-(acetyloxy)-9-fluoro-11,17-dihydroxy-, (11.beta.)-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (95.2%)
毒性情報
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Fludrocortisone acetate
vNo-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
EPA Human Health Benchmarks for Pharmaceuticals
Fludrocortisone acetate
0.001
0.004
The usual dose is 0.1 mg of fludrocortisone acetate tablets daily, although dosage ranging from 0.1 mg three times a week to 0.2 mg daily has been employed. In the event transient hypertension develops as a consequence of therapy, the dose should be reduced to 0.05 mg daily.
Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 0.043 mg/day, Lowest Therapeutic Dose (LTD): 0.0005 mg/kg-day, and Screening Dose: 0.0000002 mg/kg-day.
18-May-21
安全データ
化学と産業
応用分野
説明Fludrocortisone acetate is the acetate form of the synthetic corticosteroid fludrocortisone, which is a mineralocorticoid receptor agonist. Fludrocortisone acetate (0.1-5 μg/animal) promotes sodium retention in rats in a dose-dependent manner with 37% of sodium excreted compared with control when used at a dose of 5 μg/animal. Formulations containing fludrocortisone acetate have been used in the treatment of Addison’s disease.
一般的な説明Fludrocortisone acetate,21-acetyloxy-9-fluoro-11β,17-dihydroxypregn-4-ene-3,20-dione, 9α-fluorohydrocortisone (Florinef Acetate), isused only for the treatment of Addison disease and for inhibitionof endogenous adrenocortical secretions. It has up to about 800 times the MC activity of hydrocortisone and about 11 times the GC activity. Its potent activity stimulated the synthesis and study of the many fluorinated steroids. Although its great salt-retaining activity limits its use to Addison disease, it has sufficient GC activity that in some cases of the disease, additional GCs need not be prescribed.
上流・下流製品情報
上流原料
下流製品
関連反応
1 件
化合物ノート
読み込み中…